Trade Summary

1 week ago, ORBIMED ADVISORS LLC, serving as Dir at Braveheart Bio, Inc. (BRVE), purchased 1,940,000 shares at $18.00 per share, for a total transaction value of $34,920,000.00. Following this transaction, ORBIMED ADVISORS LLC now holds 273,333 shares of BRVE.

The trade was executed on Friday, August 7, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, August 11, 2026 at 5:27 PM ET, 4 days after the trade was made.

Braveheart Bio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.